Qureator is proud to announce its participation at ARVO 2025, unveiling its pioneering iPSC-derived 3D outer Blood-Retinal Barrier (oBRB) model. Using Curiochips™ technology, the model faithfully replicates key features of both dry and wet AMD, including drusen formation, barrier disruption, and neovascularization. In line with FDA and NIH efforts to promote human-based research and reduce animal testing, Qureator’s innovation marks a major advance in accelerating drug discovery. Visit Qureator at ARVO 2025 to learn how our technology is bridging the gap between research and real-world treatment for AMD patients globally.
https://www.linkedin.com/posts/qureatorinc_arvo2025-areyouqureating-arvo25-activity-7323918725508694017-8poV?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAAluEwBTFpLwu-91jAPnRgOUU7_S8cHYhU